Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 20/20 | 0.74 |
| ▸ | HRH1 | P35367 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121348 | 0.87 | SSTR5 (0.77) | SSTR5HRH1KCNH2HTR2B | |
| SCHEMBL1121498 | 0.87 | SSTR5 (0.75) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL1121959 | 0.87 | SSTR5 (0.75) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL1380401 | 0.85 | SSTR5 (1.00) | SSTR5HRH1KCNH2HTR2B | |
| SCHEMBL1121482 | 0.85 | SSTR5 (0.66) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL1121650 | 0.85 | SSTR5 (0.68) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL1121353 | 0.84 | SSTR5 (0.69) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL1121249 | 0.84 | SSTR5 (0.71) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL3579228 | 0.84 | SSTR5 (0.69) | SSTR5HRH1KCNH2HTR2BSSTR1 | |
| SCHEMBL1121280 | 0.84 | SSTR5 (0.71) | SSTR5HRH1KCNH2HTR2BSSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | claimed |
| EP-1924579-B1 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-02-09 | — | — | EP | claimed |
| CN-101253171-A | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | claimed |
| EP-1924579-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | claimed |
| US-20070093521-A1 | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | US | claimed |
| WO-2007025897-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | claimed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| CN-101253171-B | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | disclosed |
| EP-1924579-B1 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090163517-A1 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | BINGGELI ALFRED | 2009-06-25 | — | — | US | disclosed |
| CN-101253171-A | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | disclosed |
| EP-1924579-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-20070093521-A1 | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025897-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163517-A1 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | SSTR5, NPY5R, NPY1R | SSTR5 1/4885HRH1 233/4885KCNH2 1701/4885 |
| US-20070093521-A1 | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | SSTR5, NPY5R, NPY1R | SSTR5 1/4885HRH1 233/4885KCNH2 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.